



PRESS RELEASE

Aenova Group enlarges management team

Mohammad Naraghi new CEO of the leading pharmaceuticals producer / Marco Robert Gorgas becomes COO

Starnberg, 18 May 2016. The Aenova Group, one of the world's leading companies in the pharmaceuticals and healthcare industry, has expanded its management team. The Supervisory Board of the Aenova Holding has appointed Mohammad Naraghi, M.D., Sc.D. (51) to the position of Chief Executive Officer (CEO) effective as of 15 May 2016. He succeeds to Dr Axel Müller, who had acted as interim CEO since 2015. Dr Naraghi has acquired many years' international experience in the healthcare and life sciences industry. He will be responsible for Strategy, Marketing and Distribution as well as Research and Development, Communications, Quality and Human Resources.

The Supervisory Board appointed Marco Robert Gorgas (45) as the new Chief Operating Officer (COO), who has many years' pharmaceutical experience and had previously been Senior Vice President Global Operations of the pharmaceuticals producer STADA Arzneimittel AG. From 1 June 2016, he will be in charge of Production and Supply Chain Management.

Dr Markus Böning has already been Chief Financial Officer (CFO) of the Aenova Group since August 2015. His responsibilities include Finance, Controlling, Investor Relations, IT and Procurement.

“With these three managerial personalities, the management team of the Aenova Group is extremely well positioned. We're convinced that the management team will further intensify the Group's integration, control its operations with excellence and further reinforce Aenova's position as a leading partner to the pharmaceuticals industry,” said Stefan Zuschke, Managing Partner at BC Partners and a member of the Supervisory



Board. The key objectives of the Aenova Group in the coming years are reported to be the further extension of the service quality in farmed-out production, the optimisation of its production structure and the need to foster sustainable growth in Europe and worldwide.

Dr Mohammad Naraghi has spent nearly his entire professional life in various international managerial positions in the healthcare and life sciences industry: from 2013 to 2015, he was CEO Germany of the SYNLAB Group, the leading provider of laboratory services in Europe. He was responsible for business in Germany with approx. 4,500 employees in over 120 medical laboratories, also within hospitals. Before he became CEO at SYNLAB, at the New York Head Office of IBM he was responsible as Global Leader Healthcare and Life Sciences for the global service business with pharmaceuticals, medtech / biotech and healthcare customers.

Early stations of his professional career included the listed Dutch pharmaceuticals wholesaler and retailer Mediq, where he was responsible on the Management Board for parts of the European as well as US business. Previously, at Siemens Healthcare, he was the first CEO of the global diagnostics section, Siemens Diagnostics, which he built up following the acquisition of Diagnostic Products Corporation (LA) as well as the diagnostics business of Bayer Healthcare (NY). Previously, as a member of the Global Executive Committee at Siemens Healthcare, he was in charge of Global Business Development.

The manager, who was born near Tehran, studied medicine in Aachen, Bonn, Vienna and Pasadena (state examination), mathematics (diploma) and computational neurosciences (MSc). He earned a doctorate in Würzburg and Göttingen and was subsequently engaged as a medical practitioner in the field of cardiology and heart surgery before he joined the business consultancy firm McKinsey & Company.

From November 2009, Marco Robert Gorgas held various managerial positions with the pharmaceuticals producer STADA Arzneimittel AG, Bad Vilbel (listed on the MDAX). From 2009 to the year 2010, he was responsible for the Russian activities of STADA, the



second biggest market behind Germany. From 2010 to 2014, as Vice President he was in charge of STADA's own production sites and responsible within the scope of the STADA optimisation programme for the establishment of a global production network and for consolidating the locations. Most recently, as Senior Vice President Global Operations not only was he responsible for all Stada production sites (15 factories in Europe and Asia, with a workforce of over 3,500 employees) but also for STADA's international product transfers. Before that he spent over 10 years with the business consultancy firm Capgemini in Germany, predominantly engaged in the life science division and business transformation topics and was also a member of the extended management team of the German-speaking region. Mr Gorgas earned a diploma in business from the Technical University of Chemnitz.

About Aenova

The Aenova Group is one of the world's leading enterprises in the pharmaceuticals and healthcare industry. The spectrum of services of the Group comprises the entire value added chain of development and production of all common forms of drug administration and product groups in the field of medications and nutritional supplements. Thanks to high quality standards, innovative technologies and a clear future orientation, Aenova has developed into the European market leader in the business-to-business segment. The company, headquartered near Munich, is represented at 19 manufacturing locations worldwide. A workforce of over 4,400 employees in eleven countries contributes to the success story of this group of companies.

Press contact:

Perfect Game Communications GmbH
Susanne Jahrreiss / Ralf Geissler
Lachnerstrasse 32
D-80639 Munich
Tel: +49 30 90 52 95 – 0
Mobile Susanne Jahrreiss: +49 171 83 91 901
Mobile Ralf Geissler: +49 170 / 904 30 50
E-mail: mail@perfect-game.de